PriceTargets.com logo

Tenax Therapeutics - TENX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 235.43%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$4.77 As of 11/20/2024 01:00 AM ET
▼ -0.09 (-1.85%)

This chart shows the closing price for TENX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tenax Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TENX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TENX

Analyst Price Target is $16.00
▲ +235.43% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Tenax Therapeutics in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 235.43% upside from the last price of $4.77.

This chart shows the closing price for TENX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Tenax Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2024Leerink PartnrsUpgradeStrong-Buy
10/24/2024Leerink PartnersInitiated CoverageOutperform$16.00
10/14/2024GuggenheimInitiated CoverageBuy$16.00
9/30/2024William BlairInitiated CoverageOutperform
2/20/2024Roth MkmReiterated RatingBuy ➝ Buy
11/13/2023Roth MkmReiterated RatingBuy ➝ Buy$480.00
3/7/2023Roth CapitalReiterated RatingBuy
3/7/2023Roth MkmInitiated CoverageBuy$480.00
11/26/2021HC WainwrightReiterated RatingBuy$8,000.00
12/29/2020HC WainwrightInitiated CoverageBuy$8,000.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tenax Therapeutics logo
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Read More

Today's Range

Now: $4.77
Low: $4.77
High: $4.98

50 Day Range

MA: $4.06
Low: $3.25
High: $4.94

52 Week Range

Now: $4.77
Low: $2.77
High: $33.44

Volume

15,152 shs

Average Volume

259,766 shs

Market Capitalization

$16.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Tenax Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Tenax Therapeutics in the last twelve months: Guggenheim, Leerink Partners, Leerink Partnrs, Roth Mkm, StockNews.com, and William Blair.
View the latest analyst ratings for TENX.

What is the current price target for Tenax Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Tenax Therapeutics in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 235.4%. Guggenheim has the highest price target set, predicting TENX will reach $16.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $16.00 for Tenax Therapeutics in the next year.
View the latest price targets for TENX.

What is the current consensus analyst rating for Tenax Therapeutics?

Tenax Therapeutics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TENX will outperform the market and that investors should add to their positions of Tenax Therapeutics.
View the latest ratings for TENX.

What other companies compete with Tenax Therapeutics?

Other companies that are similar to Tenax Therapeutics include Bioanalytical Systems, Celularity, Procaps Group, ALX Oncology and Immuneering. Learn More about companies similar to Tenax Therapeutics.

How do I contact Tenax Therapeutics' investor relations team?

Tenax Therapeutics' physical mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company's listed phone number is 919-855-2100 and its investor relations email address is [email protected]. The official website for Tenax Therapeutics is www.tenaxthera.com. Learn More about contacing Tenax Therapeutics investor relations.